UnitedHealth's stock is having a rough year, down 43% so far. Jim Cramer calls it a "tragedy" on many levels. The troubles ...

A High Rate of Prescriptions Are Written. The Report examined the number of prescriptions that resulted from patient participation in a Program, concluding that the rate was “high”. In one case, the ...

Earlier versions of a spending cuts package targeted PEPFAR, the popular global AIDS relief program. The White House agreed to spare the program to avoid defections, and the spending cuts passed the ...

Note that some links may require registration or subscription. A New York man who entered an MRI room while a scan was taking ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.